Brokerage Firm Rating Update on Catalent (CTLT)

Catalent (CTLT) : Zacks Investment Research ranks Catalent (CTLT) as 4, which is a Sell recommendation. 3 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 5 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 8 research analysts is 2.25, which indicates as a Buy.

Catalent (CTLT) : 5 investment research analysts covering Catalent (CTLT) have an average price target of $26.4 for the near short term. The highest target price given by the Brokerage Firm to the stock is $30 and the lowest target is $23 for the short term. Analysts expect the variance to be within $2.7 of the average price.


For the current week, the company shares have a recommendation consensus of Buy. Also, In a research note released to the investors, Wells Fargo upgrades its rating on Catalent (NYSE:CTLT).The analysts at the brokerage house have a current rating of Outperform on the shares. Earlier, the shares were rated a Market Perform by the brokerage firm. The rating by the firm was issued on June 21, 2016.

Catalent (NYSE:CTLT): stock was range-bound between the intraday low of $23.28 and the intraday high of $23.76 after having opened at $23.31 on Wednesdays session. The stock finally closed in the red at $23.31, a loss of -6.17%. The stock remained in the red for the whole trading day. The total traded volume was 9,736,903 shares. The stock failed to cross $23.76 in Wednesdays trading. The stocks closing price on Thursday was $25.28.

Catalent, Inc. is a provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. The Companys segments include Oral Technologies, Medication Delivery Solutions, and Development and Clinical Services. The Oral Technologies segment provides advanced oral delivery technologies, including formulation, development and manufacturing of oral dose forms for prescription and consumer health products across all phases of a molecules lifecycle. The Medication Delivery Solutions segment provides formulation, development and manufacturing services for delivery of drugs and biologics, administered through injection, inhalation and ophthalmic routes, using both traditional and advanced technologies. The Development and Clinical Services segment provides manufacturing, packaging, storage and inventory management for drugs and biologics in clinical trials.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.